[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Stadler P, Putnik K, Kreimeyer T, Sprague LD, Koelbl O, Schäfer C: Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. BMC Cancer; 2006;6:279
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
  • BACKGROUND: The advantage of hyperfractionated accelerated radiation therapy for advanced head and neck cancer has been reported.
  • Furthermore, randomized trials and meta-analyses have confirmed the survival benefit of additional chemotherapy to radiotherapy.
  • We retrospectively analyzed the efficiency and toxicity of the Regensburg standard therapy protocol "SCHARC" and the overall survival of our patients.
  • Around half of the patients were diagnosed with oro-hypopharynx carcinoma (52 %), one third with tongue and floor of mouth tumors (29 %) and one fifth (19 %) suffered from H & N cancer at other sites.
  • The schedule consisted of one therapy block with 30 Gy in 20 fractions over a two week period with concomitant chemotherapy (d 1-5: 20 mg/m2/d DDP + 750-1000 mg/m2/d 5FU (cont. infusion).
  • This therapy block was repeated after a fortnight break up to a cumulative dose of 60 Gy and followed by a boost up to 70 Gy (69-70.5 Gy).
  • RESULTS: Forty patients (63 %) received both radiation and chemotherapy according to the protocol.
  • Most patients were not anemic at beginning of therapy.
  • Therefore, we could assess the influence of pre-treatment hemoglobin on survival.
  • This result suggests an influence of anemia during therapy on prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Dose Fractionation. Guideline Adherence / statistics & numerical data. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Time. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3008-15 [15860857.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1341-8 [15846296.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1015-20 [15933512.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):669-79 [16077915.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):200-5 [16024111.001]
  • [Cites] Melanoma Res. 2005 Oct;15(5):417-25 [16179869.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):757-64 [16198981.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):18-24 [16098619.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):459-66 [10661354.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Int J Biol Markers. 2000 Jul-Sep;15(3):235-6 [11012100.001]
  • [Cites] Strahlenther Onkol. 2000 Oct;176(10):475-80 [11068594.001]
  • [Cites] Strahlenther Onkol. 2001 Apr;177(4):182-8 [11370552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72 [11429213.001]
  • [Cites] Strahlenther Onkol. 2001 Sep;177(9):469-73 [11591020.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1000-7 [11844823.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4617-22 [12183417.001]
  • [Cites] Strahlenther Onkol. 2002 Aug;178(8):436-41 [12240549.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):521-6 [14509950.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1110-4 [14568798.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Acta Oncol. 1988;27(2):147-52 [3390345.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1049-91 [7713776.001]
  • [Cites] Radiother Oncol. 1997 Apr;43(1):47-51 [9165136.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):157-64 [9783887.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):856-61 [9797698.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:13-6 [9879341.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jan;108(1):73-8 [9930544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):749-54 [10386631.001]
  • [Cites] Strahlenther Onkol. 2004 Dec;180(12):805-10 [15592701.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):822-6 [15599861.001]
  • [Cites] Head Neck. 2005 Jan;27(1):36-43 [15459918.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2004;66(6):325-31 [15668532.001]
  • [Cites] Strahlenther Onkol. 2005 Feb;181(2):113-23 [15702300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1087-95 [15752888.001]
  • [Cites] J Otolaryngol. 2004 Oct;33(5):295-8 [15931813.001]
  • (PMID = 17150114.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1702360
  •  go-up   go-down


2. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ: (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia; 2006 Mar;8(3):163-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to chemotherapy is a common problem encountered in the treatment of head and neck squamous cell carcinoma (HNSCC).
  • Both produced tumors in a murine floor-of-mouth model that mimics human HNSCC, exhibiting growth and invasion into adjacent tissues.
  • Mice were randomized into three groups: vehicle control and two daily intraperitoneal (-)-gossypol treatment groups (5 and 15 mg/kg).
  • In the control group, tumors grew progressively, whereas in (-)-gossypol treatment groups, tumor growth was significantly suppressed.
  • Residual tumors remained growth-suppressed for 2 weeks after cessation of (-)-gossypol treatment.
  • Our results demonstrate that (-)-gossypol can inhibit tumor growth in an orthotopic model of aggressive HNSCC.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6627-31 [11426648.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):239-48 [11510695.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):638-44 [12150516.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213 [12162702.001]
  • [Cites] J Am Chem Soc. 2002 Oct 9;124(40):11838-9 [12358513.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):160-6 [12800189.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2856-65 [12855666.001]
  • [Cites] J Cell Physiol. 2003 Sep;196(3):532-40 [12891710.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6243-56 [13679863.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):8-14 [14605879.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):179-87 [15246875.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):445-51 [15254743.001]
  • [Cites] J Pathol. 2004 Aug;203(4):927-32 [15258995.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):121-39 [1327566.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]
  • [Cites] J Neurooncol. 1994;19(1):25-35 [7815102.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):72-100 [8950468.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jun;55(6):613-23; discussion 623-5 [9191644.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):398-403 [9790794.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2039-46 [9815595.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7757-63 [15570010.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):32-8 [15523684.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Life Sci. 2000 Oct 20;67(22):2663-71 [11105982.001]
  • (PMID = 16611409.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA83087; United States / NIDCD NIH HHS / DC / T32 DC05356; United States / NIDCR NIH HHS / DE / K08 DE014620; United States / NIDCR NIH HHS / DE / DE00452-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NIDCR NIH HHS / DE / K23 DE000452; United States / NIDCR NIH HHS / DE / DE014620-01A1; United States / NIDCD NIH HHS / DC / T32 DC005356; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BCL2L1 protein, human; 0 / Neoplasm Proteins; 0 / bcl-X Protein; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC1578526
  •  go-up   go-down


3. Kawashiri S, Kojima K, Kumagai S, Nakagawa K, Yamamoto E: Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice. Head Neck; 2001 Sep;23(9):764-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice.
  • METHODS: A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19, was implanted into the oral floor of nude mice, and cisplatin or peplomycin was administered to the mice 7 or 14 days after implantation.
  • The effects of each anticancer drug and different administration timings on cancer invasion and metastasis were investigated.
  • RESULTS: Tumor size and the ratio of proliferating cell nuclear antigen-positive cells was significantly reduced.
  • In the control group, the tumors showed grade 4C mode of invasion, whereas in the groups treated with anticancer drugs, grade 3 was observed in 77.3% of the mice, with an inhibitory effect on tumor invasion being observed.
  • The tumor stage progression in the metastatic lymph nodes was also inhibited.
  • CONCLUSIONS: Chemotherapy is effective not only for tumor diminution but also for inhibiting invasion and metastasis.
  • In light of these effects, administration of anticancer drugs may be clinically useful in this regard.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cell Line. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Disease Models, Animal. Drug Administration Schedule. Lymphatic Metastasis. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Peplomycin / administration & dosage. Peplomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505487.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 56H9L80NIZ / Peplomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Gülicher D, Aumann V, Hauptmann K, Gerlach KL: [Epitheloid leiomyosarcoma of the mouth in childhood]. Klin Padiatr; 2005 Sep-Oct;217(5):291-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epitheloid leiomyosarcoma of the mouth in childhood].
  • A six-year-old girl is presented with an increasing mass involving the anterior vestibule and the floor of the mouth.
  • According to the CWS-96-study the patient underwent preoperative chemotherapy followed by complete resection of the mandibular body with the surrounding soft tissues.
  • Recurrent tumor became evident only three months later on.
  • The further treatment consisted of tumor resection, oral chemotherapy and irradiation.
  • Nevertheless tumor control could not be achieved.
  • The patient died of progressive disease 16 months after diagnosis.
  • Diagnosis is based on histologic examination and immunohistochemistry.
  • In the presented case the lack of smooth muscle actin expression made diagnosis difficult.
  • The preoperative chemotherapy could not achieve reduction of tumor size, so that extensive surgery became necessary.
  • [MeSH-major] Leiomyosarcoma. Mouth Neoplasms
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Infant. Mouth Floor / pathology. Neoplasm Recurrence, Local. Preoperative Care. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167278.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Reuther T, Posselt NK, Rabbels J, Kübler AC: [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy]. Mund Kiefer Gesichtschir; 2006 Jan;10(1):18-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral squamous cell carcinoma Retrospective analysis of therapy results and prognosis by neoadjuvant, preoperative radio-chemotherapy].
  • Only patients treated preoperatively with combined radio-chemotherapy (carboplatin/39.6 Gy) were included.
  • The purpose of the present study was to show the therapeutic outcome and the survival rates for this regimen.
  • The floor of the mouth was the most common location (48.1%), and three out of four tumours (76.7%) had a G2 grading, while 82.9% were keratinized.
  • Grade T4 was most the common (53.4%), and all patients were operated after preoperative treatment.
  • In 82.2% of the cases, there were no tumour cells detectable microscopically (R0).
  • In 34.1% there were viable tumour cells in the cervical lymph nodes, whereas in 66.7% these cells were found in the primary tumour despite preoperative treatment.
  • The overall survival time of the disease was significantly influenced by pT (P=0.004), pN (P>0.001), R0 resections (P=0.0002), viable tumour cells in lymph node metastasis (P=0.0001), viable tumour cells in the primary (P=0.0004) and recurrence of the disease (P>0.001).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:91-3 [1639328.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):833-8 [8749208.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Apr;22(2):102-7 [8320445.001]
  • [Cites] Osterr Z Stomatol. 1983 Jun;80(6):216-27 [6583641.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:43-5 [1639309.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Mar;6(2):91-7 [12017879.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:69-70 [1322346.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Jan;2(1):11-3 [9522566.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S216-25 [10938662.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:26-9 [1639303.001]
  • [Cites] Strahlenther Onkol. 1989 Sep;165(9):647-51 [2678546.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:5-8 [1639312.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:33-6 [1639306.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):486-7 [1571117.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:108-10 [1639292.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:60-3 [1695600.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):394-7 [12076706.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:111-5 [1639293.001]
  • [Cites] JAMA. 1987 Dec 11;258(22):3286-93 [3316722.001]
  • [Cites] Plast Reconstr Surg. 1979 Sep;64(3):299-305 [382205.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:21-2 [1639300.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1968;13:30-8 [5276891.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:65-8 [1639318.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1990;35:57-60 [2373435.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:104-8 [1639291.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:13-7 [1639298.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:59-61 [1639316.001]
  • [Cites] HNO. 1993 Aug;41(8):380-4 [8407379.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Feb;52(2):149-54 [8295049.001]
  • [Cites] J Otolaryngol. 1989 Apr;18(3):105-8 [2716083.001]
  • [Cites] Zahn Mund Kieferheilkd Zentralbl. 1986;74(2):161-9 [2939663.001]
  • [Cites] Cancer. 1977 Jan;39(1):204-9 [832234.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1988 Jul-Aug;12(4):293-302 [3240611.001]
  • [Cites] Head Neck Surg. 1986 Sep-Oct;9(1):13-8 [3623928.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:86-8 [1639326.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1984 Jul-Aug;8(4):264-70 [6084570.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Feb;118(2):272-5 [9482566.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:37-9 [1639307.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):379-82 [10208674.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:48-50 [1639311.001]
  • [Cites] Mund Kiefer Gesichtschir. 2000 May;4 Suppl 1:S142-54 [10938654.001]
  • [Cites] J Laryngol Otol. 1966 Aug;80(8):831-8 [5945238.001]
  • [Cites] Dtsch Zahn Mund Kieferheilkd Zentralbl Gesamte. 1973 Feb;60(2):81-93 [4122694.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):187-90 [8275423.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Jul-Aug;14(4):242-9 [2134647.001]
  • [Cites] Plast Reconstr Surg. 1982 Apr;69(4):591-600 [7071197.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:82-6 [1639325.001]
  • [Cites] Cancer Treat Rep. 1985 Sep;69(9):933-9 [3928158.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1994;39:5-12 [8088670.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:30-3 [1639305.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Dtsch Zahnarztl Z. 1951 Nov 1;6(21):1173-80 [14936642.001]
  • [Cites] Int J Oral Maxillofac Surg. 1989 Feb;18(1):39-42 [2497209.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):217-22 [15293116.001]
  • [Cites] Mund Kiefer Gesichtschir. 1998 Mar;2(2):58-61 [9567059.001]
  • [Cites] Fortschr Kiefer Gesichtschir. 1992;37:46-7 [1639310.001]
  • [Cites] Br J Plast Surg. 1980 Apr;33(2):277-82 [6446341.001]
  • [Cites] Cancer. 1994 Nov 1;74(9 Suppl):2719-25 [7954292.001]
  • [Cites] J Am Dent Assoc. 1976 Mar;92(3):571-4 [1062459.001]
  • (PMID = 16397802.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Bachmann G, Hess A, Guntinas-Lichius O, Jungehülsing M: [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth]. HNO; 2004 Jul;52(7):627-30
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palliative surgery in squamous cell carcinoma of the anterior floor of the mouth].
  • [Transliterated title] Palliative Chirurgie bei Plattenepithelkarzinom des vorderen Mundbodens.
  • A 62 year old patient presented with a bleeding, incurable squamous cell carcinoma of the anterior floor of the mouth.
  • After four palliative surgical procedures, a definitive and a palliative radiation therapy and a palliative chemotherapy, the patient remained free of tumor in the head and neck region for 2 years after the initial treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Mouth Floor / surgery. Mouth Neoplasms / surgery. Palliative Care
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Surgical Flaps


8. Takayama O, Yokoyama J, Ito S: Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP. Auris Nasus Larynx; 2006 Jun;33(2):235-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP.
  • This tumor most frequently occurs in parotid gland.
  • This is the first report presenting the tumor in floor of the mouth.
  • Especially, there was not good therapy for recurrent cases.
  • We treated the patient with repeated recurrences three times and presented in bilateral parapharyngeal space to skullbase in this time.
  • In order to accomplish the both objections he received the superselective intra-arterial chemotherapy infused high-dose CDDP with radiation.
  • We confirmed tumor free in FDG-PET in 2 months after the treatment.
  • Now, we cannot detect any recurrence in 7 months after the treatment and he can eat anything and communicate anybody as before treated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / pathology. Carcinoma / therapy. Mouth Floor / pathology. Myoepithelioma / pathology. Myoepithelioma / therapy. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Injections, Intra-Arterial. Magnetic Resonance Imaging. Male. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446069.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Buch RS, Geisbüsch R, Kunkel M: [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma]. Mund Kiefer Gesichtschir; 2002 Sep;6(5):331-5
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma].
  • BACKGROUND: The term "paraneoplastic syndrome" describes a clinically apparent disease associated with a malignant neoplasm, which is not a direct consequence of invasive tumor growth.
  • Symptoms evolved under palliative chemotherapy with gemcitabine for inoperable metachronous squamous cell carcinoma of the tonsil following a history of two simultaneous carcinomas of the alveolar crest.
  • Digital ischemia was combined with severe pain, similar to Raynaud's syndrome, which required therapeutic intervention.
  • The treatment objective is to improve perfusion and simultaneously reduce pain.
  • [MeSH-major] Alveolar Process. Carcinoma, Squamous Cell / diagnosis. Fingers / blood supply. Ischemia / etiology. Maxillary Neoplasms / diagnosis. Mouth Floor. Mouth Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Palliative Care. Paraneoplastic Syndromes / etiology. Tonsillar Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Necrosis. Raynaud Disease / therapy. Sympathectomy. Vasodilator Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12448236.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vasodilator Agents
  •  go-up   go-down


10. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Their 5-year survival in relation to age, gender, tumor site, lymph node involvement, presence of distant metastasis, staging, differentiation, and risk factors, including betel quid (BQ) chewing, cigarette smoking, and alcohol consumption, was analyzed.
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Yang H, Liu S, Liang C, Peng W: [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan;34(1):9-11, 30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
  • OBJECTIVE: To investigate the immunological mechanism of mouse IL-2 gene therapy and the optimal lipid to DNA ratios of lipid-DNA complexed (lipoplexes) by using polycationic liposome-mediated Tumors were established in the transduction for head and neck squamous cell carcinoma (HNSCC).
  • METHODS: floor of mouth in C3H/HeJ immunocompetent mice with SCCVII cell line.
  • The supernatants of SCCVII cell and tumour tissues were collected for IL-2 expression by enzyme-linked immunosorbent assay.
  • By use of lipoplexes with L:D = 3:1, higher IL-2 expression of tumor tissues and greater activities of NK cell and CTL of murine spleen were noted in the treated group as compared with those A comparison of naked plasmid and lipid-complexed found in naked DNA and empty plasmid (EP).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy. Head and Neck Neoplasms / therapy. Interleukin-2 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Carriers. Killer Cells, Natural / immunology. Lipids. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Polyamines. T-Lymphocytes, Cytotoxic / drug effects. Transfection / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600166.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Interleukin-2; 0 / Lipids; 0 / Lipofectamine; 0 / Polyamines; 0 / polycations
  •  go-up   go-down


12. Kovács AF: Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer. Cancer Biother Radiopharm; 2005 Jun;20(3):267-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer.
  • By combining the antineoplastic activity and embolizing effect in the same drug, a more routine use seems possible.
  • A cisplatin suspension in normal saline (5 mg in 1 mL) with precipitation of microembolizing cisplatin crystals and without additional drugs was prepared.
  • The highest response rates could be seen in T1-3 tumors and tumors of the oral tongue and floor of the mouth.
  • There have been 3.5% interventional and 10% local complications, which could be significantly reduced by the use of this procedure only in cancers of the oral tongue, floor of the mouth, and mandibular alveolar ridge.
  • It could be used as an induction before definitive surgery or radiotherapy.
  • [MeSH-major] Cisplatin / chemistry. Cisplatin / therapeutic use. Embolization, Therapeutic. Mouth Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Crystallization. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Second Primary / pathology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989472.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • CONCLUSION: BSCC is a highly aggressive malignant tumor that presents in elderly patients who have a history of abuse of tobacco or alcohol, or both.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Lin CY, Wang HM, Kang CJ, Lee LY, Huang SF, Fan KH, Chen EY, Chen IH, Liao CT, Chang JT: Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1011-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
  • PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors.
  • METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively.
  • The median dose of RT was 72 Gy (range, 62-76 Gy).
  • Cisplatin-based chemotherapy was administered to 95% of the patients.
  • RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment.
  • The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001).
  • The T stage and RT technique did not affect survival.
  • CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT.
  • The primary tumor extension and RT technique did not influence survival.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cause of Death. Cisplatin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiation Injuries / pathology. Salvage Therapy / mortality. Survival Analysis. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20434273.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Pradier O, Hummers-Pradier E, Gaci Z, Jadaud D, Descrozailles JM, Gesta P, Germain T, Daban A, Hess CF: [Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992]. Cancer Radiother; 2000 Jan-Feb;4(1):32-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992].
  • [Transliterated title] Analyse rétrospective des résultats du traitement de 91 cancers de la cavité buccale de 1982 à 1992.
  • PURPOSE: To analyse retrospectively the results of different treatment regimens of carcinomas of the floor of the mouth and tongue.
  • MATERIALS AND METHODS: Between 1982 and 1992, 61 patients with carcinoma of the floor of the mouth and 30 with tongue cancer (25 stage I, nine stage II, 28 stage III, 29 stage IV) were treated in the radiotherapy department of Poitiers.
  • Nine patients with stage I tumours were treated with 70 Gy low-dose rate brachytherapy only, without nodal dissection.
  • Stage IV cases were treated either surgically if possible, or with combined chemotherapy and radiation.
  • Most relapses appeared in the first two years after treatment.
  • Eight patients (32%) with stage I cancer developed nodal relapses, isolated in five cases.
  • The remarkable observation of our study is the high incidence of nodal recurrences after local treatment of stage I tumours.
  • Therefore, local treatment is insufficient for early-stage tumours.
  • [MeSH-major] Brachytherapy. Mouth Neoplasms / radiotherapy. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10742807.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


17. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • Five-year cumulative survival rates showed significant differences between stage classifications (stage I = 91%, stage II = 73%, stage III = 63%, stage IV = 47%; p < 0.01) but not between tumor sites.
  • The 5-year cumulative survival rate was highest for oral floor cancer (80%).
  • No significant difference in regional control rates was observed between the treatment groups.
  • The 5-year survival rate for patients with cervical recurrences after primary tumor resection was 70% (n = 15).
  • In contrast, the 5-year survival rate for patients with both primary tumor resection and neck dissection was 74% (n = 14) but no significant difference was observed between these 2 groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


18. Kübler AC, Reuther T, Staff C, Haase T, Flechtenmacher C, Benner A, Scheer M, Zillmann U: [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas]. Mund Kiefer Gesichtschir; 2001 Mar;5(2):105-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas].
  • BACKGROUND: Animal tumor models are still essential for the development of new medication and therapy concepts.
  • For the field of oropharyngeal cancer only few reliable xenogeneic tumor models are available.
  • In a two-part experiment a new xenogeneic tumor model was established.
  • PART 1 OF THE STUDY: The growth rates of two different tumor cell lines were compared in the RAG-2 mouse, the SCID mouse and the Swiss nude mouse.
  • Cells from a lymph-node metastasis of an oral squamous cell carcinoma (XF-354) showed a better growth rate and clearer histology than cells from a primary squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The tumor growth rate was highest on the RAG-2 mouse, followed by the SCID mouse.
  • The Swiss nude mouse showed no tumor growth at all.
  • The combination of the XF-354 tumor cell line and the RAG-2 mouse was the most successful, with a tumor growth rate of 95%.
  • The single steps for cell cultivation and tumor implantation are described and discussed in detail.
  • Macromolecular linked photosensitizers have theoretical advantages owing to their pharmacokinetics and tumor selectivity.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Disease Models, Animal. Mesoporphyrins / pharmacology. Oropharyngeal Neoplasms / pathology. Photochemotherapy. Polyethylene Glycols / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Humans. Mice. Mice, Inbred Strains. Mice, SCID. Neoplasm Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372175.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / temoporfin-polyethylene glycol conjugate; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


19. Budach W: [Intra-arterial preoperative chemotherapy versus preoperative radiotherapy]. Strahlenther Onkol; 2001 Feb;177(2):113-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial preoperative chemotherapy versus preoperative radiotherapy].
  • [Transliterated title] Intraarterielle präoperative Chemotherapie versus präoperative Strahlentherapie.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Infusions, Intra-Arterial. Mouth Floor. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Tongue Neoplasms / drug therapy. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carotid Artery, External. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / prevention & control. Odds Ratio. Osteoradionecrosis / etiology. Preoperative Care. Quality of Life. Radiotherapy / adverse effects. Radiotherapy Dosage. Radiotherapy, Adjuvant. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11233834.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement